Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Effect of PAK1 gene silencing on proliferation and apoptosis in hepatocellular carcinoma cell lines MHCC97-H and HepG2 and cells in xenograft tumor

Subjects

Abstract

This study intends to explore the effect of the PAK1 gene silencing on apoptosis and proliferation of hepatocellular carcinoma (HCC) MHCC97-H and HepG2 cells and cells in xenograft tumor. MHCC97-H and HepG2 cells and mice with xenograft tumor in vivo were randomly divided into control, empty vector and PAK1 shRNA groups. Morphology and the expression of green fluorescent protein of MHCC97-H and HepG2 cells and cells in xenograft tumor were observed. MTT assay and flow cytometry were used to detect proliferation, cell cycle and apoptosis of MHCC97-H and HepG2 cells and cells in xenograft tumor. The expressions of PAK1, PCNA, Ki67, Cyclin E, CDK2, p21, p53, Bax and Bcl-2 were measured using the quantitative reverse transcription polymerase chain reaction and western blotting. Compared with the control and empty vector groups, number of adherent cells of MHCC97-H and HepG2 cells and cells in xenograft tumor was reduced, and green fluorescent cells became round and reduced in the PAK1 shRNA group. Cell proliferation, the cells at S phase, the mRNA and protein expressions of PAK1, PCNA, Ki67, Cyclin E, CDK2 and Bcl-2 of MHCC97-H and HepG2 cells and cells in xenograft tumor were decreased, while the cells at G1 phase, apoptosis rate, the mRNA and protein expressions of p21, p53 and Bax of MHCC97-H and HepG2 cells and cells in xenograft tumor were increased in the PAK1 shRNA group. PAK1 gene silencing decreases proliferation of MHCC97-H cells, HepG2 cells and cells in xenograft tumor through the p53/p21 pathway.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

References

  1. Lee LH, Hwang JI, Cheng YC, Wu CY, Lee SW, Yang SS, et al. Comparable outcomes of ultrasound versus computed tomography in the guidance of radiofrequency ablation for hepatocellular carcinoma. PLoS ONE. 2017;12:e0169655.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, et al. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol Biol (Paris). 2010;58:278–87.

    Article  CAS  Google Scholar 

  3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.

    Article  CAS  PubMed  Google Scholar 

  4. Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol. 2012;56:267–75.

    Article  PubMed  Google Scholar 

  5. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol. 2010;33:41–52.

    Article  Google Scholar 

  6. Trinchet JC. Hepatocellular carcinoma in 2014: current situation and future prospects. Diagn Interv Imaging. 2014;95:705–8.

    Article  PubMed  Google Scholar 

  7. Rudolph J, Crawford JJ, Hoeflich KP, Wang W. Inhibitors of p21-activated kinases (PAKs). J Med Chem. 2015;58:111–29.

    Article  CAS  PubMed  Google Scholar 

  8. Puto LA, Pestonjamasp K, King CC, Bokoch GM. p21-activated kinase 1 (PAK1) interacts with the Grb2 adapter protein to couple to growth factor signaling. J Biol Chem. 2003;278:9388–93.

    Article  CAS  PubMed  Google Scholar 

  9. Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci USA. 2011;108:7177–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Al-Maghrabi J, Emam E, Gomaa W, Al-Qaydy D, Al-Maghrabi B, Buhmeida A, et al. Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma. Int J Clin Exp Pathol. 2015;8:15895–902.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Thullberg M, Gad A, Beeser A, Chernoff J, Stromblad S. The kinase-inhibitory domain of p21-activated kinase 1 (PAK1) inhibits cell cycle progression independent of PAK1 kinase activity. Oncogene. 2007;26:1820–8.

    Article  CAS  PubMed  Google Scholar 

  12. Drozdzik M, Qian C, Xie X, Peng D, Bilbao R, Mazzolini G, et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J Hepatol. 2000;32:279–86.

    Article  CAS  PubMed  Google Scholar 

  13. Wong LL, Lam IP, Wong TY, Lai WL, Liu HF, Yeung LL, et al. IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-kappaB activation. PLoS ONE. 2013;8:e68843.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Chen L, Liu H, Liu J, Zhu Y, Xu L, He H, et al. Klotho endows hepatoma cells with resistance to anoikis via VEGFR2/PAK1 activation in hepatocellular carcinoma. PLoS ONE. 2013;8:e58413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zhan MN, Yu XT, Tang J, Zhou CX, Wang CL, Yin QQ, et al. MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1. Cell Death Dis. 2017;8:e2529.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Strzalka W, Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Ann Bot. 2011;107:1127–40.

    Article  CAS  PubMed  Google Scholar 

  17. Ma S, Yang J, Li J, Song J. The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma. Tumour Biol. 2016;37:7405–12.

    Article  CAS  PubMed  Google Scholar 

  18. Castilla C, McDonough P, Tumer G, Lambert PC, Lambert WC. Sometimes it takes darkness to see the light: pitfalls in the interpretation of cell proliferation markers (Ki-67 and PCNA). Skinmed. 2012;10:90–92.

    PubMed  Google Scholar 

  19. Fuentes M, Andrews M, Arredondo-Olguin M. Effects of high iron and glucose concentrations over the relative expression of Bcl2, Bax, and Mfn2 in MIN6 cells. Biol Trace Elem Res. 2013;153:390–5.

    Article  CAS  PubMed  Google Scholar 

  20. Fan J, Li R, Zhang R, Liu HL, Zhang N, Zhang FQ, et al. Effect of Bcl-2 and Bax on survival of side population cells from hepatocellular carcinoma cells. World J Gastroenterol. 2007;13:6053–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal. 2010;22:1003–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Wang Y, Fisher JC, Mathew R, Ou L, Otieno S, Sublet J, et al. Intrinsic disorder mediates the diverse regulatory functions of the Cdk inhibitor p21. Nat Chem Biol. 2011;7:214–21.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Shi YZ, Hui AM, Takayama T, Li X, Cui X, Makuuchi M. Reduced p21 (WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer. 2000;83:50–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Villamar Cruz O, Prudnikova TY, Araiza-Olivera D, Perez-Plasencia C, Johnson N, Bernhardy AJ, et al. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition. Oncotarget. 2016;7:76590–603.

    PubMed  Google Scholar 

  25. Chen T, Gu C, Xue C, Yang T, Zhong Y, Liu S, et al. LncRNA-uc002mbe.2 interacting with hnRNPA2B1 mediates AKT deactivation and p21 up-regulation induced by trichostatin in liver cancer cells. Front Pharmacol. 2017;8:669.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the Natural Science Foundation of Hebei Province (H2015206270) and Hebei provincial government-funded special funds for clinical medical talents in 2017. We would like to show sincere appreciation to the reviewers for critical comments on this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Li Peng.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, ZL., Liu, Gc., Peng, L. et al. Effect of PAK1 gene silencing on proliferation and apoptosis in hepatocellular carcinoma cell lines MHCC97-H and HepG2 and cells in xenograft tumor. Gene Ther 25, 284–296 (2018). https://doi.org/10.1038/s41434-018-0016-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41434-018-0016-9

This article is cited by

Search

Quick links